Francis K. Buadi

Mayo Clinic — United States

Medicine · Health Sciences

84h-index28.6kcitations973works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(586), Amyloidosis: Diagnosis, Treatment, Outcomes(326), Protein Degradation and Inhibitors(186), Chronic Lymphocytic Leukemia Research(124), Cancer Treatment and Pharmacology(117)

Publications971 total

Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front-Line Daratumumab Lenalidomide and Dexamethasone.
PubMed·2026
Cytogenetics-based Clinical Trajectories in Patients with MRD Negativity Post Autologous Transplant for Multiple Myeloma
2026Open Access
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma
Blood Cancer Journal·2026Open Access
Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia
Blood Cancer Journal·2025Open Access
Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study
Blood Advances·2025Open Access
Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)
Blood·2025
The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma
Blood·2025Open Access
Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement
Blood·2025Open Access
Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma - a single center prospective study
Blood·2025Open Access
Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia
Blood·2025Open Access
Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma
Blood·2025
Disease characteristics, treatment patterns, and outcomes of AL amyloidosis patients with high-risk FISH cytogenetics
Blood·2025
Radiomics-based identification of high-risk disease in newly diagnosed multiple myeloma
Blood·2025Open Access
AL amyloidosis: a real-world experience with CAR T-cell therapy
Blood Advances·2025Open Access
Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma
American Journal of Hematology·2025
Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
Blood Cancer Journal·2025Open Access
Expression Profile–Based Dissemination Score for Myeloma Prognostication
Clinical Lymphoma Myeloma & Leukemia·2025
Outcomes of CAR-T Cell Therapy in Patients with AL Amyloidosis
Clinical Lymphoma Myeloma & Leukemia·2025
Elevated Non-Clonal Bone Marrow Plasma Cell Fraction at Diagnosis is Associated with Improved Outcomes in Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 49Next →

Frequent Co-authors

Angela Dispenzieri(45), Shaji Kumar(44), Morie A. Gertz(44), Martha Q. Lacy(40), S. Vincent Rajkumar(38), David Dingli(38), Suzanne R. Hayman(36), Stephen J. Russell(30), Robert A. Kyle(30), John A. Lust(29), Steven R. Zeldenrust(26), Nelson Leung(20), Prashant Kapoor(16), Rafaël Fonseca(16), Philip R. Greipp(15), Vivek Roy(14), Joseph Mıkhael(13), A. Keith Stewart(12), Craig B. Reeder(11), Yi Lin(11)